Search Results - "Jun, Monika P."

Access to Chimeric Antigen Receptor T Cell Therapy for Diffuse Large B Cell Lymphoma by Snyder, Sophie, Chung, Karen C., Jun, Monika P., Gitlin, Matthew

“…Introduction Geographic access to novel oncology therapies, and the extent to which it may vary by potential sites of care, regions, and population…”
Get full text

Travel-Related Economic Burden of Chimeric Antigen Receptor T Cell Therapy Administration by Site of Care by Snyder, Sophie, Albertson, Tina, Garcia, Jacob, Gitlin, Matthew, Jun, Monika P.

“…Introduction We previously examined how expanding access to chimeric antigen receptor (CAR) T cell therapy administration sites impacted patient travel…”
Get full text

Health Care Resource Utilization and Total Costs of Care Among Patients with Diffuse Large B Cell Lymphoma Treated with Chimeric Antigen Receptor T Cell Therapy in the United States by Keating, Scott J., Gu, Tao, Jun, Monika P., McBride, Ali

“…•Chimeric antigen receptor (CAR) T-cell therapies are associated with toxicities, including cytokine release syndrome (CRS) and neurological events…”
Get full text

Treatment patterns, healthcare resource utilization, and costs in Medicare patients with diffuse large B-cell lymphoma: a retrospective claims analysis (2015-2020) by Jun, Monika P, Mutebi, Alex, Chhibber, Anindit, Liang, Chenxue, Keshishian, Allison, Wang, Anthony, Rivas Navarro, Fernando, Kalsekar, Anupama, He, Jing, Wang, Tongsheng

“…To understand treatment patterns, healthcare resource utilization (HCRU), and the economic burden of diffuse large B-cell lymphoma (DLBCL) in elderly adults in…”
Get more information

Health State Utilities for Adverse Events Associated with Chimeric Antigen Receptor T-Cell Therapy in Large B-Cell Lymphoma by Howell, Timothy A., Matza, Louis S., Jun, Monika P., Garcia, Jacob, Powers, Annette, Maloney, David G.

“…Background Chimeric antigen receptor (CAR) T-cell therapy provides effective treatment for large B-cell lymphoma (LBCL). Cost-utility analyses examining and…”
Get full text

Cytokine release syndrome and neurological event costs in lisocabtagene maraleucel–treated patients in the TRANSCEND NHL 001 trial by Abramson, Jeremy S., Siddiqi, Tanya, Garcia, Jacob, Dehner, Christine, Kim, Yeonhee, Nguyen, Andy, Snyder, Sophie, McGarvey, November, Gitlin, Matthew, Pelletier, Corey, Jun, Monika P.

“…Chimeric antigen receptor (CAR) T-cell therapies have demonstrated high response rates in patients with relapsed/refractory large B-cell lymphoma (LBCL);…”
Get full text

Practice efficiency of treatment with epcoritamab versus glofitamab in relapsed/refractory diffuse large B-cell lymphoma by Meyer, Kellie, Huang, Danmeng, O'Day, Ken, Lahue, Betsy J., Wang, Anthony, Mutebi, Alex, Brodkin, Samantha, Jun, Monika P.

“…e18919 Background: Bispecific antibodies are an emerging class of immunotherapies with demonstrated efficacy in the treatment of relapsed/refractory (R/R)…”
Get full text

Real-world outcomes with novel therapies in R/R DLBCL by Crombie, Jennifer Leigh, Jun, Monika P., Wang, Tongsheng, Mutebi, Alex, Wang, Anthony, Chibber, Anindit, Kamalakar, Rajesh, Ukropec, Jon, Blædel, Julie, Kalsekar, Anupama

“…7552 Background: Outcomes have historically been poor for patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL). Despite an increase in…”
Get full text

Racial and ethnic representation in large B-cell lymphoma trials and real-world databases by Munoz, Javier, Mutebi, Alex, Wang, Tongsheng, Zhang, Guihua, Yu, Junhua, He, Jing, Chibber, Anindit, Kamalakar, Rajesh, Jun, Monika P., Adejumo, Kelechi, Yang, Shibing, Kalsekar, Anupama

“…e19530 Background: In large B-cell lymphoma (LBCL) trials, racial and ethnic representation is difficult to determine due to underreporting in some regions, or…”
Get full text

Real-World Outcomes in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma Treated with Standard of Care: A Cota Database Analysis by Ip, Andrew, Mutebi, Alex, Wang, Tongsheng, Jun, Monika P., Kalsekar, Anupama, Rivas Navarro, Fernando, Wang, Anthony, Kamalakar, Rajesh, Sacchi, Mariana, Elliott, Brian

Get full text

Costs of Postinfusion Monitoring By Site of Care for Patients with Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL) Who Received Third-Line or Later Treatment with Lisocabtagene Maraleucel (liso-cel) in the Transcend NHL 001 and Outreach Trials by Palomba, M. Lia, Jun, Monika P., Garcia, Jacob, Lymp, James, McGarvey, November, Gitlin, Matthew, Pelletier, Corey, Nguyen, Andy

“…Background: Chimeric antigen receptor (CAR) T cell therapy is generally limited to inpatient settings; yet, exploration of outpatient infusion and monitoring…”
Get full text